BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/8/2024 7:49:58 AM | Browse: 75 | Download: 598
 |
Received |
|
2024-02-20 01:12 |
|
Peer-Review Started |
|
2024-02-20 01:12 |
|
First Decision by Editorial Office Director |
|
2024-04-17 07:56 |
|
Return for Revision |
|
2024-04-17 07:56 |
|
Revised |
|
2024-04-28 14:39 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-05-22 13:02 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-05-29 06:07 |
|
Articles in Press |
|
2024-05-29 06:07 |
|
Edit the Manuscript by Language Editor |
|
2024-06-10 01:53 |
|
Typeset the Manuscript |
|
2024-06-13 01:01 |
|
Publish the Manuscript Online |
|
2024-07-08 07:49 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Minireviews |
| Article Title |
Update on evidence-based clinical application of sodium-glucose cotransporter inhibitors: Insight to the uncommon cardiovascular disease scenarios in diabetes
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Shi-Bing Tao, Xi Lu, Zi-Wei Ye and Nan-Wei Tong |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Nan-Wei Tong, BMed, MD, MSc, Chief Physician, Director, Director, Professor, Department of Endocrinology and Metabolism, West China Hospital of Sichuan University, No. 37 Guoxue Road, Chengdu 610041, Sichuan Province, China. tongnw@scu.edu.cn |
| Key Words |
Acute myocardial infarction; Cardiovascular disease; Atherosclerosis; Atrial fibrillation; Heart failure; Diabetes; Sodium-glucose cotransporter inhibitors |
| Core Tip |
In this paper, we concentrate on updating the clinical research on sodium-glucose cotransporter inhibitors (SGLTis) for patients with type 2 diabetes who have heart failure with a preserved injection fraction, acute heart failure, atrial fibrillation, primary prevention of atherosclerotic cardiovascular disease/cardiovascular disease, and acute myocardial infarction. We reviewed the data from clinically randomized controlled trials and meta-analyses of SGLTis in patients with diabetes from the PubMed library for our review. Previous studies have indicated that certain SGLTis empagliflozin, dapagliflozin, canagliflozin, and tofogliflozin, but not sodium-glucose cotransporter inhibitor 1 (SGLT1i) exhibit relatively superior clinical safety and effectiveness for treating the abovementioned diseases. Proper utilization of SGLTis in these patients can foster clinical improvement and offer an alternative medication option for these conditions. |
| Publish Date |
2024-07-08 07:49 |
| Citation |
Tao SB, Lu X, Ye ZW, Tong NW. Update on evidence-based clinical application of sodium-glucose cotransporter inhibitors: Insight to the uncommon cardiovascular disease scenarios in diabetes. World J Diabetes 2024; 15(7): 1461-1476 |
| URL |
https://www.wjgnet.com/1948-9358/full/v15/i7/1461.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v15.i7.1461 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
